More news on SmithKline Beecham's Kytril
More news on SmithKline Beecham's Kytril
The results of a recent study published in February's Journal of Clinical Oncology shows that a single oral dose of the antiemetic Kytril is as effective as intravenous ondansetron in preventing chemotherapy-induced nausea and vomiting.
With nausea and vomiting being the most common side effects of chemotherapy, Kytril tablets exhibited comparable efficacy to intravenous ondansetron. Over 24 and 48 hours respectively, Kytril tablets achieved total control (no nausea, no emesis, or need for rescue antiemetic therapy) in 59% and 47% of patients, respectively, compared with 58% and 44% for intravenous ondansetron.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.